Alendronic acid effervescent - EffRx

Drug Profile

Alendronic acid effervescent - EffRx

Alternative Names: Alendronate effervescent; Alendronate sodium; Binosto; Effervescent alendronate; EX-101; Steovess

Latest Information Update: 10 Mar 2015

Price : $50

At a glance

  • Originator EffRx
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Male osteoporosis; Postmenopausal osteoporosis
  • Registered Osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2014 Launched for Postmenopausal osteoporosis in Italy, Portugal and Spain (PO) by December 2014
  • 31 Dec 2014 Registered for Osteoporosis in Canada, New Zealand, Russia, Ukraine, Belarus, Moldova, Turkey, United Arab Emirates, Saudi Arabia, Yemen, Oman, Jordan, Iraq, Syria, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, Kyrgyzstan, South Korea, Myanmar, Bangladesh, Thailand, Malaysia, Laos, Vietnam, Indonesia, Philippines, Taiwan, South Africa, Botswana, Namibia, Zimbabwe, Mozambique, Angola, Kenya, Ghana, Morocco, Algeria, Tunisia, Libya and Egypt (PO) by December 2014 (EffRx website, March 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top